In db/db mice, treatment with a combination of DPP-4 inhibitor and SGLT2 inhibitor exerted more beneficial effects on β-cell mass, function and maintenance of β-cell identity markers in early (7-week old) than the advanced (16-week old) phase of diabetes [55]. The gene discussed is SLC5A2; the disease is diabetes mellitus.